We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Medica 2024 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

10-Minute COVID-19 Diagnostic Test Based on Nanoparticles Identifies IgG Antibodies and Costs Only Fifth of Market Average

By LabMedica International staff writers
Posted on 04 Feb 2021
A new COVID-19 test uses technology based on nanoparticles to detect antibodies to the novel coronavirus in 10 minutes and costs only a fifth of the market average.

The test developed by researchers at the University of São Paulo’s São Carlos Chemistry Institute (IQSC-USP; São Paulo, Brazil) and Biolinker (São Paulo, Brazil) works similarly to the rapid tests available now in pharmacies. It analyzes a drop of blood, and two red LEDs light up if it detects the presence of immunoglobulin G (IgG) antibodies, which are produced in the acute phase of COVID-19 (10 days after the onset of symptoms on average). According to the researchers, the technology can easily be adapted to the novel SARS-CoV-2 variants, if necessary.

Image: 10-Minute COVID-19 Diagnostic Test Based on Nanoparticles Identifies IgG Antibodies and Costs Only Fifth of Market Average (Photo courtesy of Karla Castro/USP)
Image: 10-Minute COVID-19 Diagnostic Test Based on Nanoparticles Identifies IgG Antibodies and Costs Only Fifth of Market Average (Photo courtesy of Karla Castro/USP)

The test can be sold for less than USD 6 after it receives regulatory approval thanks to efforts by the researchers to optimize the quantity of raw materials and reagents in order to lower its production cost and develop a technology based on nanoparticles to facilitate IgG detection. The researchers combined a gold nanoparticle (which originates the red color) with a piece of the virus’s spike protein recognized by human antibodies. To develop the molecule used in the test device, the researchers worked in the laboratory to synthesize the docking tip of the spike protein, known as the receptor-binding domain (RBD), and used a recombinant DNA technology involving bacteria genetically modified to express the viral protein in vitro.

“The more antibodies there are in the blood, the brighter the red color. We believe this means the test can also be used to monitor the response to vaccination,” said Frank Crespilho, a professor at IQSC-USP and principal investigator for the study.

Related Links:
University of São Paulo
Biolinker



New
Gold Member
ANA & ENA Screening Assays
ANA and ENA Assays
Automated Blood Typing System
IH-500 NEXT
New
Human Insulin CLIA
Human Insulin CLIA Kit
New
Alpha-1-Antitrypsin ELISA
IDK alpha-1-Antitrypsin ELISA

Latest COVID-19 News

New Immunosensor Paves Way to Rapid POC Testing for COVID-19 and Emerging Infectious Diseases

Long COVID Etiologies Found in Acute Infection Blood Samples

Novel Device Detects COVID-19 Antibodies in Five Minutes